ArticleNursing research2026
Study Protocol to Characterize Symptom Experience During Immune Checkpoint Inhibitor Therapy for Cutaneous Melanoma.
Article in Nursing research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTreatment of patients with stages IIB to IV cutaneous melanoma with immune checkpoint inhibitors (ICIs) have resulted in dramatic improvements in mortality rates. With this rapid shift in treatment, significant gaps in knowledge exist regarding the effect of ICIs on patients' symptom experiences. An in-depth characterization of inter-individual differences in symptom experiences and the identification of risk factors associated with a worse symptom experience will fill this gap and assist with early detection of ICI toxicity, guide symptom management, inform treatment decision-making, and refine ICI-symptom instrument development.
objectivesAcross four ICI cycles for patients with stage IIB to IV cutaneous melanoma, study objectives are to describe the occurrence, severity, and distress of 53 symptoms; identify symptom clusters based on symptom dimensions (i.e., occurrence, severity, distress); evaluate the stability and consistency of symptom clusters across symptom dimensions and time; identify subgroups of patients with distinct symptom profiles; and evaluate for differences among the symptom profiles in demographic and clinical characteristics and levels of cancer-related stress, financial toxicity, and quality of life (QOL).
methodsThis longitudinal, descriptive study is recruiting 300 adults with stage IIB to IV cutaneous melanoma who will start an ICI regimen and following them for four cycles. Participants complete demographic, stress, financial toxicity, and QOL questionnaires prior to their first and fourth ICI cycles. Prior to each cycle, participants report the occurrence, severity, and distress of 53 symptoms using a modified version of the Memorial Symptom Assessment Scale. Symptom clusters will be identified using exploratory factor analysis. Subgroups of participants with distinct symptom profiles will be identified across the ICI cycles using latent class and latent profile analysis. Differences among the latent classes will be evaluated using parametric and nonparametric tests.
resultsParticipant recruitment began in October 2025 and will be completed in June 2027. DISCUSSION: This study will fill important knowledge gaps about inter-individual differences in risk factors for a worse symptom experience in adults with cutaneous melanoma receiving ICIs. This knowledge is critical to inform clinical assessment and monitoring of high-risk patients and to inform future biomarker research and intervention development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.